article thumbnail

Increasing patient engagement with UK clinical trials

pharmaphorum

Pharmaceutical companies often struggle to actively involve patients in the design phase of clinical trials but doing so can have huge benefits for the sustainability and success of research. Gareth has been with the Clinical Research Network since 2009.

article thumbnail

Frontiers Health Digital Innovators: Debiopharm Innovation Fund S.A.’s Tanja Dowe

pharmaphorum

Tanja Dowe is the CEO of Debiopharm Innovation Fund, the strategic investment arm of the Swiss pharmaceutical company Debiopharm. A former entrepreneur and strategy and transaction consultant, she steers the fund to invest in start-ups with disruptive technologies that transform the pharmaceutical industry. . About the author.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Health Innovators: Graeme Duncan, Advanz Pharma

pharmaphorum

In this episode of our Health Innovators series, Paul Tunnah interviews Graeme Duncan, CEO of specialty pharmaceutical company Advanz Pharma. Graeme discusses his career in the life sciences industry and how Advanz Pharma positions itself as the go-to partner for companies commercialising complex medicines in Europe.

article thumbnail

Bridging the healthcare digital divide: a gradual approach to adopting ePI

European Pharmaceutical Review

According to Eurostat, only 57 percent of people in the 55-74 age group use the internet regularly, and only 54 percent of Europeans possess basic digital skills The Pharmaceutical Group of the European Union (PGEU) presents a compelling argument against the proposed POD policy. Article 63 EMA (29 January 2020).

article thumbnail

Biogen’s $900 million settlement signals scrutiny on speaker fees

Pharmaceutical Technology

Bringing an end to a 13-year deliberation on a whistleblower lawsuit, Biogen recently agreed to pay a $900 million settlement , amidst increased government alertness on pharmaceutical fraud. In 2009, Tysabri was performing well, having yielded $776 million in sales after being first approved in 2004, as per Biogen’s 2009 financial filings.

article thumbnail

Divest to invest: the new normal in biopharma?

European Pharmaceutical Review

This heightened focus from regulators is shifting the type of deals pharmaceutical companies are willing to execute, Baral noted. These mega deals created behemoth companies that needed to spread capital too thin and included redundancies due to unrealised synergies.

article thumbnail

How to get acquisition ready – a seller’s guide to merger and acquisition in pharma

pharmaphorum

In 2018, over 60% of all new molecular entities came from smaller biopharma firms, compared with just over 30% in 2009. So, how do smaller pharmaceutical companies at the cutting edge get ready for their acquisition milestone, so they maximise their value and attractiveness?